DBV Technologies S.A. (NASDAQ:DBVT) Sees Large Increase in Short Interest

DBV Technologies S.A. (NASDAQ:DBVT) saw a large increase in short interest in July. As of July 31st, there was short interest totalling 307,100 shares, an increase of 6.3% from the July 15th total of 288,800 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily volume of 94,100 shares, the short-interest ratio is presently 3.3 days.

DBV Technologies Price Performance

Shares of DBVT traded down $0.01 during mid-day trading on Friday, hitting $0.93. The stock had a trading volume of 5,736 shares, compared to its average volume of 51,975. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $3.70. The business has a fifty day moving average price of $0.91 and a 200-day moving average price of $1.26. The firm has a market cap of $89.98 million, a P/E ratio of -1.11 and a beta of 0.68.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period last year, the business posted ($0.26) earnings per share. As a group, research analysts expect that DBV Technologies will post -1.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DBVT has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st. StockNews.com initiated coverage on DBV Technologies in a research report on Sunday. They issued a “hold” rating for the company. Finally, JMP Securities lifted their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Wednesday, July 31st.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in DBV Technologies stock. Cowen AND Company LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.